BioXell S.p.A. invites Shareholders to its Annual Shareholders' Meeting

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Milan, Italy, April 6, 2009 - BioXell S.p.A. (SIX: BXLN) invites its
shareholders to its Annual Shareholders' Meeting to be held, in
second call, on April 30, 2009 at 10:30 a.m. at the Zunfthaus zur
Waag in Zürich, in order to discuss and resolve on the following

AGENDA

1. Approval of the Statutory Financial Statements of BioXell
S.p.A. as of December 31, 2008, the Directors' Report and the
Supplementary Note, as well as the Report of the Board of Statutory
Auditors and the Report of the External Auditors, and any related
resolution;
2. Approval of the reduction of the number of the members of
the Board of Directors and any related resolution;
3. Election of the Chairman and the members of the Board of
Directors and any related resolution;
4. Approval of the remuneration of the members of the Board
of Directors and any related resolution;
5. Election of the Chairman and the members of the Board of
Statutory Auditors and any related resolution;
6. Approval of the remuneration of the members of the Board
of Statutory Auditors and any related resolution.

The invitation with the detailed agenda and proposals was published
today in Il Sole 24 Ore and tomorrow in Le Temps and the Neue Zürcher
Zeitung.

Right to participate

Shareholders who wish to attend the meeting are required to send to
the Company, within the deadline set forth below, the confirmation of
ownership certificate (comunicazione dell'intermediario) as required
by Italian law. For this purpose, Shareholders may request their
respective bank to send the aforesaid certificate to the Company. The
Company must receive the confirmation of ownership certificate no
later than April 24, 2009.

For further information on the attendance procedure for the meeting,
please refer to the Company's website at www.bioxell.com.

Proxies
Shareholders will be able to be represented by proxy holders,
provided that the related proxies are drafted in compliance with
Italian law, and in particular with Section 2372 of the Italian civil
code. Accordingly, proxies must be in writing and cannot be granted
either to the members of the Board of Directors, the members of the
Board of Statutory Auditors, or to the Company's employees.

For further information on the formalities relating to granting
proxies, please refer to the Company's website at www.bioxell.com.

Documentation
Pursuant to, and within the terms of the Italian law, all documents
relating to the items of discussion of the agenda will be made
available at the Company's registered office, during the 15 days
preceding the first call of the meeting. These documents together
with more detailed information on the agenda items will also be
available on the Company's website as of April 9, 2009.

With regards to items 3 and 5 of the agenda, please refer to section
5.3 and 14, respectively, of the Articles of Association, as well as
to the relating information which is available on the Company's
website at www.bioxell.com. The Company must receive the lists, the
relevant documentation and the confirmation of ownership certificate
by those Shareholders presenting the lists no later than April 14,
2009.

In order to facilitate Shareholders with the formalities, those lists
deposited at the Company's premises by April 14, 2009, shall be
published by the Company in at least one of the following Italian
newspapers Corriere della Sera, Repubblica, Il Sole 24 Ore, as well
as in the Swiss newspapers Le Temps and Neue Zürcher Zeitung, and
made available on the Company's website on April 17, 2009

Shareholders are invited to convene at the venue of the meeting at
least one hour before the beginning of the meeting in order to
facilitate registration proceedings.
Shareholders may obtain further information from Alvise Sagramoso,
Chief Administrative Officer of the Company; Telephone No.
+390221049550; E-mail address: Alvise.Sagramoso@bioxell.com.

About BioXell
BioXell (SWX: BXLN) is a biopharmaceutical company focused on the
discovery and development of drugs that exploit novel mechanisms of
action to treat important urological, inflammatory, and related
disorders with significant unmet medical needs. The Company was
founded in 2002 as a spin-out from Roche. BioXell's strategic goal is
to become a fully integrated pharmaceutical company by maximizing the
commercial potential of its product portfolio and leveraging existing
platforms into profitable partnerships.

BioXell's lead compound, Elocalcitol, derived from its proprietary
VD3 (Vitamin D3) technology platform, has successfully completed a
Phase IIb clinical trial for Benign Prostatic Hyperplasia (BPH).
Elocalcitol is currently in a Phase IIb clinical trial for Overactive
Bladder (OAB) of which data are expected in April 2009.
More on BioXell can be found at: www.bioxell.com

For further information, please contact:

BioXell
S.p.A.
Dynamics Group SA

Alvise Sagramoso/Angela
Evans Christophe Lamps
Tel: +39 02 210 49
51
Tel: +41 (0)22 308 6222
Fax: +39 02 210 49
529 Fax:
+41 (0)22 308 6236
alvise.sagramoso@bioxell.com
cla@dynamicsgroup.ch
angela.evans@bioxell.com

This press release can be downloaded at www.bioxell.com.

Disclaimer
This press release does not constitute or form part, or all, of any
offer or invitation to sell or issue, or any solicitation of any
offer to purchase or subscribe for, any securities, nor shall part,
or all, of these materials or their distribution form the basis of,
or be relied on in connection with, any contract or investment
decision in relation to any securities. This press release contains
forward-looking statements based on the currently held beliefs and
assumptions of the management of BioXell, which are expressed in good
faith and, in their opinion, reasonable. Forward-looking statements
involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, financial condition, performance,
or achievements of BioXell, or industry results, to differ materially
from the results, financial condition, performance or achievements
expressed or implied by such forward-looking statements. Given these
risks, uncertainties and other factors, recipients of this document
are cautioned not to place undue reliance on these forward-looking
statements. BioXell disclaims any obligation to update these
forward-looking statements to reflect future events or developments.

--- End of Message ---

bioXell S.p.A
via Olgettina 58 Milan Italy

WKN: A0J3MW; ISIN:
IT0004069933 ;
Listed: Main Market in SIX Swiss Exchange;
Copyright © Hugin AS 2009. All rights reserved.